A Phase I/II Single Center Study to Assess Tolerability and Feasibility of Infusions of Allogeneic Expanded Haploidentical Natural Killer (NK) Cells in Patients Treated With High Dose Melphalan Chemotherapy and Autologous Stem Cell Transplantation for a Multiple Myeloma
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety of expanded NK cell infusion
One year after infusion.
Yes
Martin Stern, MD
Principal Investigator
Dep. of Hematology, Petersgraben 4, CH-4031 Basel
Switzerland: Swissmedic
NK_MM_01
NCT01040026
December 2010
October 2017
Name | Location |
---|